A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancer
Phase 2
- Conditions
- Thymic cancer
- Registration Number
- JPRN-UMIN000001358
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Presence of pleural or pericardial effusion that cannot be controlled by a procedure. 2)Presence of brain tumor with clinical symptoms. 3)Superior vena cava syndrome. 4)Interstitial pneumonitis. 5)Presence of other active malignancy. 6)Acute intercurrent infection or complications 7)History of serious allergy to medical drugs. 8)Uncontrolled psychiatric disease. 9)pregnancy or lactating patients 10)Myasthenia gravis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate (RECIST criteria)
- Secondary Outcome Measures
Name Time Method Overall survival, Progression survival, Safety